Akebia Therapeutics Announces Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Akebia Therapeutics (AKBA) PT Lowered to $18 at Needham & Company
August 9, 2018 1:40 PM EDTNeedham & Company lowered its price target on Akebia Therapeutics (NASDAQ: AKBA) to $18.00 (from $20.00) while maintaining a Buy rating.
Analsyt Chad Messer notes vadadustat pivotal readouts were pushed out. "We continue to expect that INNO2VATE will be fully enrolled by YE:18; however,... More
